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Abstract
Th17 cells are implicated in host defence and autoimmune diseases. CD28/B7 co-stimulation is involved in the induction
and progression of autoimmune diseases, but its role in controlling murine Th17 cell fate remains to be clarified. We here
report that soluble anti-CD28 mAb suppressed the differentiation of anti-CD3-stimulated naı ¨ve CD4
+ T cells into IL-17-
producing cells. CD28 co-stimulation reduced the frequency of proliferating cells that produce IL-17. We provide evidence
for an IL-2 and IFN-c-dependent mechanism of CD28-mediated IL-17 suppression. CD28 blockade of Th17 development was
correlated with a decrease rather than an increase in the percentage of Foxp3
+ T cells. In APC/T cell co-cultures, mature
dendritic cells (DC) were less efficient than immature DC in their ability to support Th17 cell differentiation, while CTLA4-Ig,
an agent blocking CD28/B7 and CTLA4/B7 interactions, facilitated both murine and human Th17 differentiation. This study
identifies the importance of B7 co-stimulatory molecules in the negative regulation of Th17 development. These
unexpected results caution targeting the CD28/B7 pathways in the treatment of human autoimmune diseases.
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Introduction
Th17 cells play a central role in autoimmune inflammatory
conditions such as multiple sclerosis (MS) [1], rheumatoid arthritis
(RA) [2] and Crohn’s disease [3]. Th17 cells are also involved in
the protection against several pathogens including Klebseilla
pneumoniae, Staphylococcus aureus, Mycobacteria tuberculosis and Candida
albicans [4]. These cells are characterised by the expression of the
transcription factor RORct and the production of the cytokines
IL-17, IL-22, IL-6 and tumor necrosis factor-a (TNF-a). The in
vitro differentiation of the murine Th17 cell lineage depends on the
synergy between transforming growth factor-b (TGF-b) and IL-6,
combined with the neutralization of IFN-c and IL-4. TNF-a and
IL-1b act as amplifiers, while IL-23 stabilizes the Th17 phenotype
[5,6,7,8,9]. The combination of TGF-b and IL-21 constitutes an
alternative pathway for Th17 development [10]. The activation
and differentiation of CD4
+ T helper lymphocytes into Th1 or
Th2 cells requires both T cell receptor/MHC-peptide specific
recognition and co-stimulatory signals. The best-defined co-
stimulatory pathway involves the B7 family, where B7.1 (CD80)
and B7.2 (CD86) molecules on antigen presenting cells interact
with CD28 and CD152 (CTLA4) on T cells [11,12,13]. However,
the precise role of these co-stimulatory molecules in the regulation
of Th17 development remains unclear. The rationale for assessing
the role of CD28 signalling in Th17 differentiation stemmed from
reports demonstrating that treatment of experimental autoimmune
encephalomyelitis (EAE) with anti-CD80 or anti-CD86 Abs or
multiple injections of CTLA4-Ig resulted in enhanced disease
severity [14,15]. Additionally, B7 deficiency facilitates autoimmu-
nity, and this, among other possible mechanisms, was attributed to
a loss or inactivation of regulatory T cells [12,16]. Moreover, the
development of diabetes in Non-obese Diabetic (NOD) mice is
exacerbated by deletion of CD28 [17].
Finally, the clinical report of the development of ulcerative colitis
during CTLA4-Ig (abatacept) therapy in a patient with RA
reinforces our hypothesis that costimulatory molecules may regulate
human Th17 development [18]. We here demonstrate that CD28
signalling suppresses Th17 differentiation, while CTLA4-Ig block-
ade promotes mouse and human Th17 polarization in vitro.
Materials and Methods
Mice
All 8- to 12-week-old BALB/c mice were housed in our breeding
colony and animal care facility under specific pathogen-free
conditions. All experimental protocols were approved by the Centre
de Recherche du Centre Hospitalier Universitaire de Montre ´al
(CRCHUM) and the Canadian Council on Animal Care.
Culture medium, Antibodies and Reagents
Mouse cells were cultured in complete RPMI-1640 medium
(Wisent Inc., St-Bruno, QC, Canada) supplemented with 10%
fetal bovine serum (FBS), Penicillin (500 U/ml), Streptomycin
(500 mg/ml), HEPES buffer (10 mM), and 2-ME (1 mM),
(GIBCO-BRL, Invitrogen corp., Carlsbad, CA, USA). LPS (E.Coli)
was obtained from Sigma-Aldrich (St. Louis, MO, USA).
Recombinant mouse IL-1, IL-6 and recombinant human TGF-
b1 were purchased from R&D Systems (Minneapolis, MN, USA).
Recombinant mouse GM-CSF and anti-murine IL-2 were
purchased from PeproTech (Rocky Hill, NJ, USA). Mitomycin-
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The following clones were purchased from American Type
Culture Collection (Rockville, MD, USA) and purified in our
laboratory: GK1.5 (anti-CD4, biotinylated); R46A2 (anti-IFN-c);
11B11 (anti-IL-4), IM7.8.1 (anti-CD44, biotinylated). Allophyco-
cyanin, FITC or PerCP-conjugated anti-mouse CD4, PerCP-
conjugated streptavidin, PE-conjugated anti-mouse CD40, CD86
and IA/IE, allophycocyanin-conjugated Annexin V, allophyco-
cyanin-conjugated anti-mouse IL-2 and IFN-c, anti-mouse CD28
and purified mouse CTLA4-Ig fusion protein were purchased
from BD Biosciences (Mississauga, ON, CA). PE- or allophyco-
cyanin-conjugated anti-mouse IL-17A, APC/Cy7-conjugated
anti-mouse CD25, APC/Cy7 or PE/Cy7-conjugated streptavidin
and anti-mouse CD3 were purchased from Biolegend (San Diego,
CA, USA). Recombinant murine IL-23 and anti-mouse Foxp3-PE
staining kits were purchased from eBioscience (San Diego, CA,
USA). PE-conjugated anti-mouse CD62L was purchassed from
Caltag Laboratories (Burlingame, CA, USA). Carboxyfluorescein
diacetate succinimidyl ester (CFSE) was purchased from Invitro-
gen (Carlsbad, CA, USA).
Cell purification and in vitro generation of Th17 cells
Total CD4
+ T cells were purified from spleen and peripheral
lymph nodes (LNs) by positive selection using immunomagnetic
beads according to the manufacturer’s protocol (EasySep Biotin
Selection Kit, StemCell Technologies Inc, Vancouver, BC, CA).
For some experiments, naı ¨ve CD4
+ (CD4
+CD62L
highCD44
low),
naı ¨ve CD4
+CD25
2 (CD4
+ CD62L
highCD44
lowCD25
2) and
memory CD4
+ (CD4
+CD62
lowCD44
high) T cells were isolated
from splenocytes and peripheral lymph nodes (LNs) by sorting
using a Becton Dickinson FACSAria II cell sorter (BD Bioscience).
Cells (1610
6 cells/ml) were activated with plate-bound anti-mouse
CD3 (5 or 10 mg/ml) in flat bottom 96-well plates in the presence
of the Th17-promoting cytokine cocktail IL-1-a, IL-6, IL-23
(10 ng/ml) and TGF-b1, (1 ng/ml) with or without anti-mouse
CD28 mAb (2 mg/ml). For some experiments, 10 mg/ml of
neutralizing anti-mouse antibodies (anti-IL-2, anti-IFN-c and
anti-IL-4) were added to the cultures. After 4–5 days, recovery
of viable cells was assessed by trypan blue (GIBCO-BRL,
Invitrogen corp.) exclusion. The cells were restimulated during
6 h with PMA/ionomycin. For Treg cell experiments, total CD4
+
T cells, CD4
+CD25
2 and CD4
+CD25
+ T cells were separated
from spleen or peripheral LNs using the EasySep Negative
Selection Mouse CD4
+ T cell Enrichment Kit followed by the
mouse CD25-Microbeads Kit (Miltenyi Biotec, Auburn, CA,
USA) according to the manufacturer’s protocols. CD4
+CD25
2 T
cells (1610
6 cells/ml) were cultured alone or in the presence of
CD4
+CD25
+ T cells at two different CD4
+CD25
2/CD25
+ ratios
(1/1, 4/1) for 4–5 days and activated on anti-CD3 (10 mg/ml)
coated plates under Th17 conditions in the presence or the
absence of anti-mouse CD28 mAb.
Culture of CD4
+ T cells with BMDC
Bone marrow-derived DC (BMDC) were generated as described
previously [19]. In some experiments, BMDC were activated
overnight with 1 mg/ml of LPS (mBMDC) and stained for CD86,
CD40, or MHCII (IA/IE) expression. CD4
+ T cells (2.5610
5
cells/ml) were purified from spleens as described and stimulated
with soluble (2 mg/ml) or coated anti-CD3 (5 mg/ml) in the
presence of immature (untreated) or mature (treated with LPS)
mitomycin-C-treated BMDC at different CD4
+/BMDC ratios (2/
1, 1/1, 1/2). The cultures were supplemented with the Th17
promoting cytokine cocktail. In some experiments, mouse
CTLA4-Ig (20 mg/ml) fusion protein was added to CD4
+/
mBMDC cultures.
Intracellular cytokine staining
For intracellular staining, cells were restimulated for 6 h with
PMA (phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and
ionomycin (1 mg/ml) in the presence of brefeldin A (1 mg/ml) per
1610
6 cells. Cells were stained in the presence of Fcc Blocker
(Clone 24G2) with FITC, PerCP or allophycocyanin-conjugated
anti-CD4 antibodies, fixed and permeabilized (BD Cytofix/
Cytoperm, BD Biosciences or eBioscience for Foxp3 staining).
Cells were assessed for IL-17, IFN-c, IL-2 and Foxp3 expression.
Data were acquired on a Becton Dickinson FACS Calibur and
analyzed with Cell Quest software (BD Bioscience).
Labeling Naı ¨ve CD4
+CD25
2 T cells with CFSE
Naı ¨ve CD4
+CD25
2 (CD4
+CD62L
highCD44
lowCD25
2) T cells
were isolated from splenocytes and peripheral lymph nodes (LNs)
by sorting using a Becton Dickinson FACSAria II cell sorter (BD
Bioscience). CD4
+ T cells were washed and resuspended at final
concentration of 10
7/mL in EasySep buffer (PBS containing 2%
FBS and 1 mM EDTA). CFSE was added at a final concentration
of 1 mM and incubated for 15 min at 37 degree. The reaction was
stopped by washing cells twice with RPMI 1640, containing 10%
FBS. CFSE-labeled naı ¨ve CD4
+CD25
2 T Cells (1610
6 cells/ml)
were activated as previously described with plate-bound anti-
mouse CD3 under Th17 conditions with or without anti-mouse
CD28 mAb. The cells were monitored on day 4–5 for CFSE cell
dilution and cytokine expression.
Assessment of apoptosis
The CD4
+ cells were stimulated as described with anti-CD3 in
the absence or presence of anti-CD28, harvested from cultures at
48 h, 72, 96 and 120 h, to monitor apoptosis. Briefly, cells were
washed and resuspended in 100 ml of Annexin binding buffer
(10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2)a t1 610
6/ml with 5 ml of allophycocyanin-
conjugated Annexin V (BD Biosciences) and incubated 5 minutes
at room temperature. The samples were then analyzed by flow
cytometry.
ELISA
The production of IL-17 and IFN-c was measured with the IL-
17 Duoset ELISA kit (R&D Systems) and the OptEIA Mouse IFN-
c ELISA set (BD Biosciences), respectively, according to the
manufacturer’s protocols.
Quantitative RT-PCR analysis
Total RNA was extracted from cell cultures using the RNeasy
mini kit (Qiagen, Mississauga, ON) and reverse-transcribed using
the cDNA reverse transcription kit (Applied Biosystems, Foster
City, CA). Quantitative real-time PCR was performed using an
ABI Prism 7900HT Sequence Detection System (Applied
Biosystems) (1 PCR cycle, 95uC, 10 minutes; 40 PCR cycles,
60uC, 1 minute, 95uC, 15 seconds). cDNA was amplified in a
10 ml final reaction mix containing TaqMan Universal PCR
Master Mix (Applied Biosystems) and corresponding TaqManH
Gene Expression Assays (Mm00444241_m1 (IL-22),
Mm00439619_m1 (IL-17a), Hs99999901_s1 (Eukaryotic 18s
rRNA), Applied Biosystems). Signals were analyzed by the ABI
Prism Sequence Detection System software version 2.2 (Applied
Biosystems). The comparative Ct method for relative quantifica-
tion was used, whereby all threshold cycles (Ct) are first
CD28 Co-Stimulation and Th17
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rRNA). The normalized values were then divided by the average
delta Ct value of anti-CD3-stimulated samples. Here, the cytokine
expression is represented as a fold-change relative to CD3-
stimulated cells6SEM.
Human DC/T co-cultures
Human PBMC were obtained from healthy volunteers in
compliance with the Institutional (CR-CHUM) Research Ethics
Committee. Naı ¨ve CD4
+ T were isolated from total PBMC using
the human CD4
+ Naı ¨ve T cell Enrichment Kit (Stem Cell
Technologies). The purity of adult human naı ¨ve CD4
+ T cells was
.99% CD4
+CD45RA
+ and comprised ,0.5% single
CD45RORA
+ cells as assessed by flow cytometry analysis. Naı ¨ve
CD4
+ T cells were co-cultured for 5 days with mature monocyte-
derived DC at a DC/T ratio of 1/25 in Yssel’s medium (Gemini
Bio-product, West-Sacramento, CA, USA) supplemented with 2%
human AB serum (Wisent) in the presence of 100 ng/ml of soluble
anti-CD3 (OKT-3; Janssen-Ortho) with or without human
CTLA4-Ig fusion protein (5 mg/ml) (Abatacept, Orencia, Bristol-
Myers Squibb, Canada) for 5 days. Primed T cells were expanded
for 5 days in the presence of IL-2 (20 U/ml, R&D Systems). T
cells were restimulated for 6 h with PMA (5 ng/ml) and
ionomycin (0.5 mg/ml) in the presence of monensin (3 mM).
Intracytoplasmic staining was performed using BD Cytofix/
Cytoperm and anti-IL-17-APC (R&D System). Culture superna-
tants were collected after re-stimulation and IL-17, IL-22 and
IFN-c were detected by ELISA (R&D Systems).
Statistical Analysis
Statistical analyses were performed using the GraphPad Instat
program.
Results
CD28 co-stimulation negatively regulates the
development of naı ¨ve CD4
+ (CD4
+CD62L
highCD44
low)T
cells into IL-17-producing T helper cells
We here hypothesised that the CD28/B7 co-stimulatory
pathway controls Th17 development. We first examined the effect
of anti-CD28 mAb on Th17 differentiation and cytokine mRNA
expression. CD4
+ T cells isolated from the spleen or peripheral
LNs of wild-type BALB/c mice were activated on plate-bound
anti-CD3 under Th17 polarizing conditions in the presence or
absence of soluble anti-CD28 mAb. After 4–5 days of primary
culture, cells were re-stimulated with phorbol 12-myristate 13-
acetate (PMA) and ionomycin. As depicted in Fig. 1, anti-CD28
mAb strongly inhibited IL-17 production by anti-CD3 stimulated
CD4
+ T cells as determined by intracellular cytokine staining and
enzyme-linked immunosorbent assay (ELISA) (Fig. 1, A–B and
data not shown). Accordingly, anti-CD28 mAb diminished the
proportion of IL-17-producing cells by 82.8% (mean inhibi-
tion68.1%, n=14). In contrast, IFN-c production was signifi-
cantly increased as reflected by a decreased IL-17/IFN-c ratio
after CD28 engagement (Fig. 1C). Quantitative real-time PCR
(qRT-PCR) analysis of mRNA revealed a reduction in IL-17 and
IL-22 expression (Fig. 1D). Since CD4
+ T cells are comprised of
,90% naı ¨ve (CD4
+CD62L
highCD44
low) and ,10% of memory
(CD4
+CD62L
low) T cells, we next compared naı ¨ve and memory T
cells for their ability to differentiate into Th17 in the presence or
absence of CD28 mAb. We showed that CD28 engagement
strongly inhibited naı ¨ve T cell differentiation into Th17 without
preventing their proliferation (Fig. 2A). Indeed, IL-17 was
exclusively produced by dividing cells and CD28 co-stimulation
decreased the proportion of proliferating cells that produced IL-
17. In contrast, ex vivo isolated memory T cells represented a minor
source of IL-17 (less than 2% IL-17
+CD4
+ T cells) that was not
modulated by CD28 mAb (Fig. 2A). Under Th17 polarizing
conditions, memory T cells produced large amounts of IFN-c
when compared to naı ¨ve T cells.
Figure 1. CD28 co-stimulation inhibits in vitro generation of IL-
17 producing CD4
+ T cells. Purified CD4
+ T( 1 610
6) cells from spleen
(A–C) and LNs (A) were stimulated with plate-bound anti-CD3 with or
without anti-CD28 under pro-Th17 conditions for 4–5 days and
restimulated for 6 h with PMA/Ionomycin in the presence of brefeldin
A. (A) CD4
+ T cells were stained intracellularly for IL-17 and IFN-c.
Numbers represent the percentage of events in each quadrant. (B)
Cumulative data of the percentage of CD4
+IL-17 and IFN-c positive T
cells after restimulation as assessed by intracytoplasmic staining. Data
represent the mean6SEM of at least ten independent experiments. (C)
The ratio of the percentage of IL-17
+ to IFN-c
+ cells among CD4
+ T cells.
(D) qRT-PCR analysis of IL-17 and IL-22 mRNA expression in purified
CD4
+ T cells cultured as described in A. Data are expressed as
mean6SEM of four experiments. P values were calculated using the
two-tailed, paired Student’s t test, *, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0005087.g001
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cells that have been differentiated into Th17 with anti-CD3 in the
absence of co-stimulation. To this end, CD4
+ T cells activated
during 4–5 days with coated anti-CD3 under Th17 conditions
were restimulated with anti-CD3 and IL-23 in the presence or
absence of anti-CD28 mAb. Interestingly, we found that anti-
CD28 mAb significantly enhanced IL-17 production upon re-
stimulation, demonstrating that CD28 co-stimulation did not
inhibit fully differentiated Th17 cells (Fig. 2B). As expected, anti-
CD3-activated CD4
+ T cells were not polarized into Th17 cells in
the absence of the pro-Th17 cocktail, but instead resulted in the
development of IFN-c2producing T cells, which was further
augmented by CD28 co-stimulation (Fig. 2C). We conclude that
anti-CD28 mAb inhibits naı ¨ve CD4
+ T cells polarization into
Th17.
TCR avidity and CD28 co-stimulation regulates Th17
development
We next determined the EC50 of anti-CD28 mAb (effective
concentration of anti-CD28 mAb resulting in a 50% inhibition of
IL-17 secretion) on Th17 differentiation by supplementing CD3-
stimulated T cells with increasing doses of mAb. Suppression was
observed with concentrations as low as 0.06 mg/ml, Th17
development was almost entirely abrogated at 1 mg/ml and the
EC50 of anti-CD28 mAb was 0.1 mg/ml (Fig. 3A, left). The
enhancement in IFN-c secreting CD4
+ T cells was inversely
correlated with the frequency of IL-17-producing cells (Fig. 3A,
right). To examine whether impairment of IL-17 production with
anti-CD28 mAb was dependent on the TCR-signalling intensity,
CD4
+ T cells were stimulated with titrated doses of anti-CD3 and
a fixed amount of anti-CD28 mAb. As shown in Fig. 3B the
Figure 2. CD28 co-stimulation did not modulate memory Th17 cells. (A) FACS sorted naı ¨ve CD4
+ (CD4
+CD62L
highCD44
low), CFSE-labeled
naı ¨ve CD4
+ CD25
2 (CD4
+CD62L
highCD44
lowCD25
2) and memory CD4
+ (CD4
+CD62L
lowCD44
high) T cells were cultured with anti-CD3 in the presence or
absence of anti-CD28 mAb under pro-Th17 conditions for 4–5 days. Shown is one representative experiment out of at least three. (B) CD4
+ T cells
were stimulated with anti-CD3 under Th17 polarizing conditions for 4–5 days and restimulated with plate-bound anti-CD3 in the presence or absence
of IL-23, and with or without anti-CD28 mAb for 2 days. Data represent the mean6SD of five to seven independent experiments. (C) Purified CD4
+ T
cells were cultured with anti-CD3 in the presence or absence of anti-CD28 mAb without adding Th17 differentiation cytokines for 4–5 days. Data are
the mean6SD of 2 independent experiments. (A–C) Cells were restimulated for 6 h with PMA/Ionomycin in the presence of brefeldin A. Naı ¨ve and
memory CD4
+ T cells were stained intracellularly for IL-17 and IFN-c and CFSE-labeled naı ¨ve CD4
+CD25
2 for Il-17. Numbers represent the percentage
of positive cells in each gate. P value were calculated using the two-tailed, paired Student’s t test, **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0005087.g002
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+ T cells producing IL-17 was significatively
augmented with high doses of immobilized anti-CD3 mAb.
Moreover, the strongest CD28 inhibitory signal for Th17
differentiation was delivered to T cells stimulated with high anti-
CD3 concentration. This inhibition of Th17 differentiation could
not be attributed to increased cell death. Indeed, the recovery of
viable cells as well as apoptotic cell death rate were similar in CD3
and CD3 plus CD28 co-stimulated CD4
+ T cells cultures from the
early (48 h) to a late time point of restimulation (between 96 and
120 h) (Fig 3D).
CD28 co-stimulation inhibits Th17 differentiation via IFN-
c and IL-2-dependent mechanisms
CD28 signalling is reported to enhance cytokine production that
includes IL-2, IL-4 and IFN-c secretion in activated CD4
+ T cells
[20], we found that anti-CD28 mAb increased the proportion of
IL-2-producing cells (Fig. 4A) as well as IFN-c2producing cells in
anti-CD3-stimulated CD4
+ T cells (Fig. 1 and 3). Under Th17
polarizing conditions, neutralization of IL-2 or IFN-c but not IL-4
partially overcame CD28 blockade and lead to increased IL-17
production. Nonetheless, the frequency of IL-17
+CD4
+ T cells
Figure 3. TCR avidity and CD28 co-stimulation signals regulate Th17 development. (A) Purified CD4
+ T were stimulated with plate-bound
anti-CD3 (5 mg/ml) and titrated doses of soluble anti-CD28 mAb under Th17 polarizing conditions. Cells were stained intracellularly for IL-17 and IFN-c
expression. The data shown is one representative experiment out of two. (B) CD4
+ T cells were stimulated with titrated doses of plate-bound anti-CD3
in the presence or absence of soluble anti-CD28 mAb (2 mg/ml). Data represent the mean6SD of four independent experiments. (C) Cumulative data
of viable CD4
+ T cell recovery after stimulation with anti-CD3 (5 mg/ml) the presence or absence of anti-CD28 mAb (2 mg/ml). Data are the mean6SD
of 3 (LNs) to 20 (spleen) independent experiments. (D) CD4
+ T cells were stimulated with coated anti-CD3 (10 mg/ml) in the presence or absence of
soluble anti-CD28 under Th17 conditions and analyzed at different time points for the percentage of apoptotic cells (Annexin V binding positivity).
Mean values6SD obtained from at least three separate experiments are presented. P values were calculated using the two-tailed, paired Student’s t
test, *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0005087.g003
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stimulation. However, treatment with both anti-IL-2 and anti-
IFN-c mAbs restored IL-17 production and thus completely
abrogated the effect of CD28 engagement (Fig. 4B).
Since IL-2 partly mediated the inhibitory effect of anti-CD28
mAb on Th17 development, we postulated that the suppressive
function of IL-2 operates through the expansion of Foxp3
+ T cells.
We here found that the percentage of Foxp3
+CD4
+ T cells was
decreased rather than increased after CD28 signalling (Fig. 5A).
We next directly addressed the contribution of Treg to the CD28-
mediated suppression of Th17 differentiation by CD25
+CD4
+ T
cell depletion and reconstitution experimental approaches
(Fig. 5B). The IL-17 production was reduced in anti-CD3-
stimulated CD4
+CD25
2 T cells. Co-cultures of CD4
+CD25
2 T
cells and Treg at different CD4
+CD25
2/CD25
+ T cells ratio
enhanced Th17 differentiation. Of notes, Treg were recovered at
lower proportion than expected at the end of the cultures that may
be best explained by the overwhelming non Treg cell proliferation
in the cultures (Fig. 2A and data not shown). Nonetheless, anti-
CD28 mAb did not increase the frequency of IL-17
+Foxp3
+ or IL-
17
+Foxp3
2 cells that were almost undetectable in CD25
+ T cell-
depleted polarised cultures (Fig. 5C).
Mature DC inefficiently support Th17 differentiation
The observations that Th17 differentiation can be suppressed by
high levels of co-stimulation in an APC-free system led us to
examine the ability of immature versus mature dendritic cells (DC)
to drive Th17 development. Unstimulated (immature) or LPS-
stimulated (mature) mitomycin C-treated bone marrow-derived DC
(BMDC) (Fig. 6A) were cocultured with CD4
+ T cells under Th17
differentiation conditions. As shown in Fig. 6B to E, the maturation
status of the BMDC dictated the fate of Th polarization toward
Th17. When CD4
+ T cells were differentiated in the presence of
mature BMDC, we observed a significant decrease in the
percentage of Th17 cells and, as expected, an opposing effect on
IFN-c producing cells (Fig. 6B to D). Hence, immature BMDC
induced higher frequencies of IL-17
+CD4
+ T cells when compared
to their mature counterparts (Fig. 6E). Furthermore, increased
CD4
+ T cell proliferation was observed with mature BMDC under
Th17 polarizing conditions containing TGF-b, suggesting that the
inhibition of IL-17 secretion was unlikely related to a reduced
expansion of CD4
+ T cells (data not shown).
CTLA4-Ig enhances Th-17 differentiation
To evaluate the role of B7.1 and B7.2 co-stimulatory molecules
on Th17 differentiation, we used CTLA4-Ig, which interrupts the
CD28/B7 pathway. CD4
+ T cells were co-cultured with graded
numbers of mature-BMDC under Th17 polarizing conditions in
the presence or absence of CTLA4-Ig. We found that CTLA4-Ig
significantly augmented the frequency of IL-17
+CD4
+ T cells
(Fig. 7, A and B). The proportion of IL-17-producing cells among
CD4
+ T cells co-cultured with mature BMDC at a 1/1 CD4
+/DC
ratio in the presence of CTLA4-Ig was similar to the percentage
induced with half the number of DC and in the absence of
CTLA4-Ig. Thus, lowering the mature DC/T cell ratio or
interrupting B7 costimulatory pathways favoured Th17 differen-
tiation.
Human monocytes and conventional DC, but not monocytes-
derived DCs activated by microbial stimuli, induced Th-17
priming [21].We therefore determined whether CTLA4-Ig
enhanced human Th17 differentiation in APC/T cells co-cultures.
To this end, adult CD45RA
+CD4
+ T cells were cultured with
mature monocyte-derived DC in the presence or absence of
CTLA4-Ig but in the absence of exogenous cytokines or anti-IFN-
c mAb. Our data indicate that CTLA4-Ig significantly increased
naı ¨ve CD4
+ T cell differentiation into IL-17 and IL-22-producing
cells, thereby confirming in human in vitro studies our observations
in murine DC/CD4
+ co-cultures (Fig. 7C).
Figure 4. The CD28-driven inhibition of Th17 differentiation is mediated by IL-2 and IFN-c production. Purified CD4
+ T cells were
stimulated with plate-bound anti-CD3 in the presence or the absence of soluble anti-CD28 mAb under Th17 polarizing conditions. (A) The
percentages of IL-2
+CD4
+ T cells from 7 independent experiments (mean6SEM). (B) CD4
+ T cells were cultured in the presence or absence of anti-
mouse IL-4, IFN-c or IL-2 alone or in combination. The data shown are representative of 1 experiment out of 3 (dot plots, left panel). The cumulative
data from 2–6 independent experiments are shown in the right panel. P values were calculated using the two-tailed, paired Student’s t test, *, P,0.05;
**, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0005087.g004
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In this study, we provide strong evidence for an inhibitory role
of CD28 in the development of naı ¨ve CD4
+ T cells into IL-17-
producing T helper cells with no modulation of IL-17 expression
in memory CD4
+ T cells. We here demonstrate in vitro that ligation
of CD28 with a monoclonal antibody results in inhibition of Th17
differentiation whereas CTLA4-Ig blockade enhances it during
APC/T cell interactions. The extent of suppression of Th17
differentiation was regulated by the strength of TCR and co-
stimulatory signals.
We explored some of the cellular mechanisms whereby CD28
engagement inhibited Th17 differentiation. CD28 co-stimulation
decreased the frequency of Th17 proliferating cells without
reducing their rate of cell division. Moreover, anti-CD28 mAb
did not augment early or late apoptosis in anti-CD3-stimulated T
cells cultures. Since CD28 signalling did not alter the recovery of
viable cells at the end of the cultures, we propose that the
decreased proportion of IL-17
+ cells may result from an
impairment of Th17 differentiation or an arrest of IL-17
production by Th17 proliferating cells. However, CD28 ligation
during secondary cultures did not suppress but rather significantly
enhanced IL-17 production in Th17 differentiated cells.
Although the importance of IL-6, TGF-b, IL-21 and IL-23 in
Th17 development has been clearly established, less is known about
physiological antagonists of Th17 responses. Th1 and Th2
cytokines negatively regulate the differentiation of Th17 cells. The
addition of IL-12, IFN-c or IL-4 suppresses either IL-23 or TGF-b
and IL-6-induced differentiation of Th17 cells [5,22,23]. CD28
signalling enhances IFN-c and IL-2 secretion in activated CD4
+ T
cells [20]. In agreement with these observations, we found that the
enhancement in IFN-c and IL-2-secreting CD4
+ T cells was
inversely correlated with the frequency of IL-17-producing cells.
IFN-c neutralization partially overcame CD28-mediated Th17
suppression. When combined, anti-IL-2 and anti-IFN-c mAbs
abrogated the effect of CD28 engagement. IL-2 and IL-27 inhibit
Th17differentiation[24,25].IL-27cansuppressthedevelopment of
Th17 responses at least by inducing IL-10-producing cells [26]. The
Figure 5. Inhibition of Th17 differentiation by anti-CD28 mAb is not correlated with a expansion of Foxp3
+ T cells. Purified CD4
+ T
cells were stimulated with plate-bound anti-CD3 in the presence or the absence of soluble anti-CD28 mAb under Th17 polarizing conditions. (A) The
proportion of Foxp3
+CD4
+ T cells. Data from 8 independent experiments are shown. (B and C) CD4
+, CD4
+CD25
2 T cells and CD4
+CD25
2 T plus
CD4
+CD25
+ T cells (at 1/1, 4/1 CD25
2/CD25
+ T cell ratios) were stimulated as described. Numbers indicate the percentage of IL-17 and IFN-c-
expressing CD4
+ T cells (B) and IL-17 and Foxp3-expressing cells (C). One of 2 representative experiments is shown. P values were calculated using the
two-tailed, paired Student’s t test, **, P,0.01.
doi:10.1371/journal.pone.0005087.g005
Figure 6. Mature BMDC inefficiently support Th17 differentiation. CD4
+ T cells were cultured with immature or mature BMDC at a 2/1 CD4
+/
BMDC ratio in the presence of anti-CD3 under Th17 conditions. (A) BMDC were stimulated with LPS (1 mg/ml) and stained for CD40, CD86, or MHCII
(IA/IE) expression. The mean fluorescence intensity are shown. Data are representative of one experiment out of three. (B) Cells were stained
intracellularly for IL-17 and IFN-c. Shown is one representative experiment out of 6. (C) Cumulative data of the percentage of CD4
+IL-17 and IFN-c
positive T cells after restimulation as assessed by intracytoplasmic staining. Data represent the mean6SEM of 6 independent experiments. (D) The
ratio of the percentage of IL-17
+ to IFN-c
+ cells among CD4
+ T cells. (E) CD4
+ T cells (2.5610
5 cells) were cultured with immature or mature BMDC at
three different CD4
+/BMDC ratios (2/1; 1/1; 1/2) as described in A. Data represent the mean6SD of 4 independent experiments. P values were
calculated using the two-tailed, paired Student’s t test, *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0005087.g006
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PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e5087Figure 7. CTLA4-Ig favours Th17 development. (A) CD4
+ T cells were cultured with mature BMDC at three different CD4
+/mBMDC ratios (2/1; 1/
1; 1/2) in the presence of anti-CD3 under Th17 conditions. CTLA4-Ig (20 mg/ml) was added to cultures with a 1/1 CD4
+/mBMDC cell ratio. Cells were
stained intracellularly for IL-17 and IFN-c. Shown is one representative experiment out of 4. (B) CD4
+ T cells were stimulated as in A. Data represent
the mean6SD of 4 experiments. (C) Human naı ¨ve CD4
+ T cells were co-cultured with activated monocyte-derived DC in the presence or absence of
CTLA4-Ig (5 mg/ml), expanded in IL-2 and restimulated. IL-17, IL-22 and IFN-c secretion was assessed in the culture supernatants and cells were
stained for intracellular IL-17. Shown are 3 independent experiments (ELISA, left panel) and 1 representative out of 3 experiments (intracytoplasmic
staining, right panel). P values were calculated using the two-tailed, paired Student’s t test, *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0005087.g007
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co-stimulation (data not shown). IL-2 is a well-known T cell growth
factor, yet, IL-2 deficiency is associated with severe multi-organ
autoimmune disease characterised by the overproduction of IL-17
[24,27]. These observations lead to the findings that IL-2 inhibits
Th17 differentiation and promotes Treg differentiation [28].
In addition to the thymus-derived naturally occurring regulatory
T cells (nTreg), naı ¨ve T cells can acquire Foxp3 expression and
differentiate into induced Treg cells (iTreg) in peripheral tissues.
TGF-b inducesFoxp3expressionandiTregcell differentiationfrom
CD4
+CD25
2 T cells in vitro and in vivo [29,30,31]. Co-stimulation
through CD28 impairs TGF-b mediated induction of Foxp3
expression in naı ¨ve T cells [32]. Our data indicate that CD28 co-
stimulation decreased the percentage of Foxp3
+ T cells under Th17
conditions. Although Th17 and Treg differentiation are controlled
by reciprocal molecular pathways, naı ¨ve T cells activated with
TGF-b and IL-6 can differentiate into Th17 cells in the presence of
nTreg [6,8,33]. Our results are consistent with reports showing that
Treg cells facilitate the differentiation of Th17 cells in a pro-
inflammatory cytokine milieu [34]. Furthermore, regulatory T cells
can be reprogrammed into Th17 cells [35]. T cells producing TGF-
b that promote Th17 cell differentiation are absolutely required for
the induction of EAE in vivo [36]. During an extracellular pathogen-
driven inflammation, TGF-b (Treg) suppresses Th1 and Th2
differentiation and IL-6 impairs effector T cell responsiveness to
Treg, allowing de novo differentiation of protective IL-17-producing
T cells from naı ¨ve precursors. At the same time, CD28 co-
stimulation may somehow limit Th17 differentiation to attenuate
tissue damage. Nonetheless, since CD28 engagement alters the
Th17/Th1 ratio toward Th1, under some circumstances it may
aggravate autoimmunity [37,38]. Taken together, in a Th17-
promoting milieu, CD28 co-stimulation augments IFN-c and IL-2
production and impairs Th17 polarization.
We next found that mature DC were less efficient than immature
DC at driving Th17 polarization and that CTLA4-Ig favoured
Th17 differentiation. These data strongly suggest that B7.1 and
B7.2 are involved in the regulation of Th17 differentiation but do
not exclude the role of additional pairs of co-stimulatory/inhibitory
molecules. Hence, other co-stimulatory molecules may override the
absence of B7 co-stimulationfor T cell activation and differentiation
into Th17 cells [39]. In support of our in vitro observations, several
studies have demonstrated that interfering with B7 co-stimulatory
pathways may alter the development or the course of Th17/Th1-
associated autoimmune diseases in vivo [40]. Notably, B7.1/B7.2
deletion in SJL mice increases their susceptibility to EAE in contrast
with the resistance to EAE observed in B7.1/B7.2
2/2 C57BL/6
mice[41], suggesting that genetic background and B7 costimulatory
molecules may dictate the outcome of the Th17 responses in
absence of costimulation. In that regard, our unpublished
observations indicated that anti-CD28 mAb significantly alter
anti-CD3 stimulated CD4
+ T cell differentiation into Th17 in
BALB/c but not C57BL/6 mice (data not shown). In addition,
while MOG induces EAE in wild type (CD28
+/+) C57BL/6 mice, it
induces immune-mediated meningitis (EAM) in CD28
2/2 C57BL/
6 mice, which is characterized by an infiltrate within the
leptomeninges composed primarily of polymorphonuclear neutro-
phils [42]. T cell-derived IL-17 mediates the stimulation of
neutrophil mobilization [43]. Also, B7-2-deficient NOD mice
spontaneously develop autoimmune peripheral polyneuropathy
[44]. Furthermore, inhibition of IL-17 prevents the development
of arthritis in vaccinated mice challenged with Borrelia burgdorferi,
while CD28 deficiency exacerbates joint inflammation upon Borrelia
burgdorferi infection, resulting in the development of chronic Lyme
arthritis[45,46,47].Finally,reducedco-stimulationineitherB7.1or
B7.2-deficient recipients resulted ina dramaticaccelerationofcolitis
induction following transfer of CD4
+CD45RB
high cells [48,49].
Recently, the efficacy of CTLA4-Ig has been investigated in human
clinical trials to prevent transplant rejection, and in the treatment of
RA and psoriasis vulgaris [50]. We here showed that CTLA4-Ig
significantly increased human naı ¨ve CD4
+ T cell differentiation into
IL-17 and IL-22-producing cells, thereby confirming in human in
vitro studies ourpresentobservations inmurine DC/CD4
+ T cellco-
cultures. These findings revealed the importance of B7.1 and B7.2
as negative regulators of human Th17 development. Considering
human genetic variability, different individuals may have distinct
requirements for costimulatory molecules to control Th17 devel-
opment and the pathogenesis of autoimmune diseases. Thus, our
data invoke caution when interfering with B7 co-stimulatory
pathways for therapies, a concept largely debated in the literature
[51,52].
In conclusion, we identified an unexpected role for the B7/
CD28 pathway in the regulation of Th17-associated inflammatory
responses. These in vitro observations should be taken into
consideration for the management of patients under B7-based
immunotherapy for the treatment of autoimmune diseases and
other immune-mediated disorders.
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